In addition to its ability to block both EGFR- and cMET-mediated downstream signaling, the antibody exerts its anti-tumor effects through various Fc-mediated mechanisms, such as ADCC and ACDP (37, 38). This evidence concerns the gene EGFR and neoplasm.